Alzamend Neuro, Inc.
50 W. Broadway
Suite 300
Salt Lake City
Utah
84101
United States
Tel: 949-346-5822
Website: https://alzamend.com/
About Alzamend Neuro, Inc.
Alzamend Neuro is a development stage biotechnology company which has licensed a patented mutant peptide developed by Dr. Chuanhai Cao at the college of Pharmacy of the University of South Florida (USF) and USF- Health Byrd Alzheimer’s Institute to develop a cell based therapeutic vaccine as an immunotherapy to prevent or slowdown Alzheimer’s disease. This therapy is not only target on the pathological molecule that is associated to AD, but also is able to fix the impaired immune system associated to AD developmentYEAR FOUNDED:
2016
LEADERSHIP:
CEO: Phil Mansour
CTO: William B. Horne
Chairman: Milton “Todd” Ault
CAREER:
Please click here for Alzamend Neuro's job opportunities.
64 articles about Alzamend Neuro, Inc.
-
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
10/5/2022
Alzamend Neuro, Inc. today announced it has dosed its first healthy adult subject in its Phase IIA multiple ascending dose (“MAD”) study of AL001 in subjects with dementia related to Alzheimer’s.
-
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
-
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
9/29/2022
Alzamend Neuro, Inc. today announced that it submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its immunotherapy product candidate ALZN002.
-
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
9/22/2022
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has received a notification letter (the “Compliance Notice”) from the Listing Qualifications Staff of the Nasdaq.
-
FDA Weekly Review looks at the FDA's actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.
-
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
7/18/2022
Alzamend Neuro, Inc. today announced that it has received a written response to its meeting request relating to its Type B Pre-Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (the “FDA”).
-
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
6/3/2022
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational.
-
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
5/17/2022
Alzamend Neuro, Inc. today announced that it has submitted a Pre-IND (investigational new drug) meeting request for AL001 and supporting briefing documents to the U.S. Food and Drug Administration (“FDA”) for the treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder (“PTSD”).
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
May has been fruitful for research into the prevention and diagnosis of Alzheimer’s disease, the mechanisms behind early symptoms and potential treatments.
-
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
5/5/2022
Alzamend Neuro, Inc. today announced that the first patient with mild to moderate Alzheimer’s disease (“Alzheimer’s”) has been dosed in a 12-month Phase IIA multiple ascending dose (“MAD”) study for dementia related to Alzheimer’s.
-
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
4/28/2022
BitNile Holdings, Inc., a diversified holding company announced its wholly owned subsidiary, Digital Power Lending, LLC has made an additional investment in Alzamend Neuro, Inc., a related party and early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders.
-
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
4/28/2022
Alzamend Neuro, Inc. announced that Digital Power Lending, LLC, a wholly owned subsidiary of BitNile Holdings, Inc., a diversified holding company, has made an additional investment in the Company.
-
The possible addition of a new lithium-based drug to the list of available therapeutics is important because many physicians are reluctant to prescribe lithium.
-
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s
4/11/2022
Alzamend Neuro, Inc. today announced that it contracted with Altasciences Clinical Kansas (“ Altasciences ”) and iResearch Atlanta, LLC (“iResearch”) to manage and conduct, respectively, its Phase IIA multiple ascending dose (“MAD”) study in patients with mild to moderate Alzheimer’s Disease (“Alzheimer’s”).
-
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board
4/4/2022
Alzamend Neuro, Inc. today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
3/28/2022
Alzamend Neuro, Inc. today announced that it has received the full data set from its Phase 1 clinical trial for AL001.
-
Alzamend Neuro is looking to commence a Phase II multiple ascending dose study of lead compound, AL001, in Alzheimer's disease during the second quarter of this year.
-
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
12/17/2021
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive topline data from its Phase 1 clinical trial for AL001.